The estimated Net Worth of Wendy S Arnold is at least $577 Thousand dollars as of 5 July 2022. Ms Arnold owns over 15,000 units of Frequency Therapeutics Inc stock worth over $8,047 and over the last 5 years she sold FREQ stock worth over $18,754. In addition, she makes $550,373 as Chief People Officer at Frequency Therapeutics Inc.
Sign up
Ms Arnold FREQ stock SEC Form 4 insiders trading
Ms has made over 4 trades of the Frequency Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 15,000 units of FREQ stock worth $4,500 on 5 July 2022.
The largest trade she's ever made was exercising 15,000 units of Frequency Therapeutics Inc stock on 5 July 2022 worth over $4,500. On average, Ms trades about 3,857 units every 16 days since 2020. As of 5 July 2022 she still owns at least 26,824 units of Frequency Therapeutics Inc stock.
You can see the complete history of Ms Arnold stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Wendy S. Arnold biography
Wendy S. Arnold is the Chief People Officer at Frequency Therapeutics Inc.
What is the salary of Ms Arnold?
As the Chief People Officer of Frequency Therapeutics Inc, the total compensation of Ms Arnold at Frequency Therapeutics Inc is $550,373. There are 4 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
How old is Ms Arnold?
Ms Arnold is 49, she's been the Chief People Officer of Frequency Therapeutics Inc since . There are 12 older and 4 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
What's Ms Arnold's mailing address?
Wendy's mailing address filed with the SEC is 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Insiders trading at Frequency Therapeutics Inc
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer, and Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
What does Frequency Therapeutics Inc do?
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
What does Frequency Therapeutics Inc's logo look like?
Complete history of Ms Arnold stock trades at Frequency Therapeutics Inc
Frequency Therapeutics Inc executives and stock owners
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Lucchino,
President, Chief Executive Officer, Co-Founder, Director -
Christopher Loose,
Co-Founder, Chief Scientific Officer -
Carl LeBel,
Chief Development Officer -
David L. Lucchino,
Co-Founder, Pres, CEO & Director -
Wendy S. Arnold,
Chief People Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Robert Langer,
Independent Director -
Marc Cohen,
Lead Independent Chairman of the Board Director -
Joel Marcus,
Independent Director -
Michael Huang,
Independent Director -
Timothy Barberich,
Independent Director -
Carlo Tanzi,
IR Contact Officer -
Cynthia Feldmann,
Independent Director -
Dana Hilt,
Chief Medical Officer -
Ajay Rai,
Vice President - Business Development -
Richard Mitrano,
Vice President of Finance and Operations -
Wendy Arnold,
Chief People Officer -
William Mclean,
Co-Founder, Vice President - Biology and Regenerative Medicine -
Dr. Carl P. LeBel,
Chief Devel. Officer -
Dr. Christopher R. Loose,
CoÂ-Founder & Chief Scientific Officer -
Dr. William W. Chin M.D.,
Sr. VP of Translational Medicine -
Dr. Dana C. Hilt,
Chief Medical Officer -
Dr. Jeff Hrkach,
Sr. VP of Technology Devel. -
Richard J. Mitrano,
VP of Fin. & Operations -
William J. McLean Ph.D.,
Co-founder & Sr. VP of Hearing Biology and Translational Research -
Quentin Mc Cubbin,
Chief Manufacturing Officer -
James E Deerfield Mgmt L.P....,
-
Peter P. Pfreundschuh,
Chief Financial Officer -
Michael Bookman,
General Counsel and Secretary